Azacitidine
Consolidation Therapy
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Consolidation Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pyrotinib Sun Yat-sen University | Phase 2 | CCC |
Tislelizumab Sun Yat-sen University | Phase 2 | CCC |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II Sun Yat-sen University | Phase 2 | CCC |
Venetoclax The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →